<DOC>
	<DOC>NCT00114777</DOC>
	<brief_summary>The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.</brief_summary>
	<brief_title>Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant</brief_title>
	<detailed_description />
	<mesh_term>Abatacept</mesh_term>
	<criteria>Subject is a firsttime recipient of a kidney transplant from a deceased donor. Specific donor criteria Donor age &lt;10 years Subjects receiving a concurrent solid organ or cell transplant (lung, heart, etc.) Subjects with a positive Tcell lymphocytotoxic crossmatch. Subjects who are positive for Hepatitis B or C, or HIV Active TB History of cancer in the last 5 years History of substance abuse Specific laboratory results are exclusionary Mammography suspicious for cancer Allergy to iodine For Longterm extension studySubjects who have completed three years of study treatment (through Week 156)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>